# A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus

> **NCT04501107** · PHASE1 · COMPLETED · sponsor: **Adocia** · enrollment: 32 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)
- **DRUG:** Administration of Ready-to-use BioChaperone insulin lispro (IMP2)
- **DRUG:** Administration of US-approved Humalog® (IMP3)
- **DRUG:** Administration of EU-approved Humalog® (IMP4)

## Key facts

- **NCT ID:** NCT04501107
- **Lead sponsor:** Adocia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-03
- **Primary completion:** 2020-11-03
- **Final completion:** 2020-11-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501107, "A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04501107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*